TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00685399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 subcutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 subcutaneous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN 457
Description: AIN457 low dose (i.v)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN 457
Description: AIN457 low dose (i.v)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN 457
Description: AIN457 low dose (i.v)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 high dose (i.v)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 high dose (i.v)
Study: NCT00941993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoresis System (Acclarent)
Description: Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
Study: NCT01825668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant Sterols

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High cholesterol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03901196

Intervention type: DIAGNOSTIC_TEST
Intervention: Elemental analysis
Description: LIBS multi elemental analysis of the specimen
Study: NCT00617981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThermoDox
Description: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 5% Dextrose Solution
Description: Single 30 minute intravenous infusion
Study: NCT00948298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
Study: NCT04154202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Bone Scan: three-phase planar Bone Scan and a SPECT/CT \[perfusion, blood pool and SPECT/CT of the relevant region of interest (ROI), and a whole-body planar late bone scan\].
Study: NCT03470779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
Study: NCT00685399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 high dose (i.v)
Study: NCT03470779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Treatment group participants will participate in weekly group physiotherapy and psychotherapy sessions as part of the standard program procedure.
Study: NCT02006082

Intervention type: DEVICE
Intervention: Telemedicine video-consultation (TVC)
Description: All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
Study: NCT02270151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyDiagnostick
Description: Diagnostick strategy with MyDiagnostick
Study: NCT02726802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy vs. primary care interventions
Description: Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy vs. primary care interventions
Description: Subjects with acute (\< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
Study: NCT01595893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Vitamin D 3
Description: 40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol 812 N
Description: Neutral oil of esters extracted from coconut and palm kernel
Study: NCT03716921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short antibiotics treatment
Description: Patients randomized in this arm will pursue antibiotic administration until visit 3 weeks after D0
Study: NCT00409682

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight \[BW\] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
Study: NCT00990717

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK-92 cells
Description: Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2
Study: NCT00041782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin)
Description: 200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
Study: NCT00578955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% Azithromycin and 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Azithromycin
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Dexamethasone
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Study: NCT02526043

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic hepatectomy
Description: The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open hepatectomy
Description: The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
Study: NCT04437238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KeepWell tool
Description: KeepWell is standalone eHealth application aimed at supporting the self-management of older adults with multimorbidity, and it has the following features: (i) lifestyle advice for any combination of the top 10 chronic conditions affecting older adults); (ii) an avatar health coach that walks users through a health prioritization and goal setting exercise; (iii) a health risk questionnaire (HRQ) covering health (chronic diseases), lifestyle (physical activity, diet, smoking, alcohol, caffeine, bladder health), and social and emotional well-being (social frailty, isolation, loneliness) dimensions; (iv) an evidence-based, customized Action plan; (v) an interactive lifestyle tracker; (vi) journaling; (vii) and a health resources library. A health coach avatar leads users through a health priority and goal setting exercise that allows them to create a customized action plan based on guideline recommendations for lifestyle changes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control - Usual care
Description: Participants allocated to the control condition will receive care as usual.
Study: NCT01742364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioject ID Pen
Description: Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle and syringe
Description: Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
Study: NCT01474213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine group
Description: 1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil group
Description: target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
Study: NCT02070068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PINPOINT System
Study: NCT02722512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat Shock Protein Peptide Complex-96 (HSPPC-96)
Description: The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heat Shock Protein Peptide Complex-96 (HSPPC-96)
Description: The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Resection
Description: Clinically-indicated removal of the tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Resection
Description: Clinically-indicated removal of the tumor

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Focal Radiation Therapy
Study: NCT03414801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen Exposure
Description: Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen Exposure
Description: Subjects will undergo two exposure sessions, one week apart, of up to 1 hour depending on the subject's symptom severity and pulmonary function. During the exposure, subjects will be exposed to cat dander and levels of cat allergen, Fel d1, will be measured using sampling pumps with attached filters.
Study: NCT05788757

Intervention type: DEVICE
Intervention: Optetrak Total Knee System
Description: Total Knee Arthroplasty using Exactech's Optetrak branded components.
Study: NCT01732848

Intervention type: DRUG
Intervention: BMS-986094/INX-08189

Intervention type: DRUG
Intervention: Placebo matching BMS-986094/INX-08189
Study: NCT02456766

Intervention type: DEVICE
Intervention: FibroTouch

Intervention type: DEVICE
Intervention: FibroTouch

Intervention type: DEVICE
Intervention: FibroTouch

Intervention type: DEVICE
Intervention: FibroTouch

Intervention type: PROCEDURE
Intervention: Liver Biopsy

Intervention type: PROCEDURE
Intervention: Liver Biopsy

Intervention type: PROCEDURE
Intervention: Liver Biopsy

Intervention type: PROCEDURE
Intervention: Liver Biopsy
Study: NCT02213562

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 200 mg of chrysanthemum flower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of chrysanthemum flower oil

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg of chrysanthemum flower oil
Study: NCT01451879

Intervention type: DRUG
Intervention: Rituximab
Description: Clinically prescribed immune modulation regimen dosage determined by local medical provider.

Intervention type: DRUG
Intervention: Miglustat
Description: Clinically prescribed immune modulation regimen dosage determined by local medical provider.
Study: NCT01919242

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer

Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
Study: NCT02525614

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon Standard Keel
Description: Implantation of Knee Prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon Short Keel
Description: Implantation of Knee Prosthesis
Study: NCT03390699

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Microbial profile
Description: microbiological testing
Study: NCT00278512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
Study: NCT01842048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External-beam radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Study: NCT03574064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucagon-Like Peptide-2 (GLP-2)
Description: Glucagon-Like Peptide-2 (GLP-2) injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose-dependent insulinotropic polypeptide (GIP)
Description: Glucose-dependent insulinotropic polypeptide (GIP) injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2+GIP
Description: GLP-2+GIP injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection.
Study: NCT03458455

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging
Description: Vessel Architectural Imaging is an MRI-based tumor diagnostic framework providing a powerful tool for non-invasive, in vivo assessment of diagnostic biomarkers relevant for these new therapy forms; microvascular function and tumor oxygenation.

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery
Description: A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.
Study: NCT02089490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEVELIA® implantation
Description: Skin substitute implantation followed by ultra-thin epidermal graft
Study: NCT01134653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jump Stretch
Description: distraction with early mobilization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jump Stretch
Description: distraction with early mobilization
Study: NCT04025619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tape
Description: Sports tape
Study: NCT01989507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral counseling for smoking cessation
Description: Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral counseling for smoking cessation
Description: Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
Study: NCT02534948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance group therapy
Description: The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
Study: NCT04498923

Intervention type: DRUG
Intervention: Bupivacaine, dexamethasone, epinephrine
Description: Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg

Intervention type: DRUG
Intervention: Bupivacaine, dexamethasone, epinephrine
Description: Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
Study: NCT03458455

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery
Description: A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery
Description: A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery
Description: A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.

Intervention type: RADIATION
Intervention: Stereotactic Radiosurgery
Description: A non-surgical radiation therapy used to treat tumors of the brain. It can deliver precisely-targeted radiation in fewer high-dose treatments than traditional therapy, which can help preserve healthy tissue.

Intervention type: DRUG
Intervention: Ipilimumab, nivolumab or pembrolizumab
Description: A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.

Intervention type: DRUG
Intervention: Ipilimumab, nivolumab or pembrolizumab
Description: A type of therapy that uses substances to stimulate the immune system to help the body fight cancer by blocking inhibitory receptors on lymphocytes to overcome immune tolerance.
Study: NCT03616184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
Study: NCT04413630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family workshop
Description: The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
Study: NCT03043001

Intervention type: DRUG
Group type: OTHER
Intervention: Memantine
Description: All the subjects will receive add-on memantine for 12 week
Study: NCT01730898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study product containing lutein
Description: delivered in capsule form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study product containing lutein
Description: delivered in capsule form
Study: NCT02355002

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.